Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex
PubMed Full text in PMC Similar studies Analyze with GEO2R
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 (RNA-Seq)
PubMed Full text in PMC Similar studies
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex (Exome-seq)
PubMed Full text in PMC Similar studies SRA Run Selector
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex (RNA-seq)
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex (ChIP-seq)
Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex (DNA methylation)
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]
ChIPSeq data from melanoma cancer cell line CHL-1 after Bromodomain and extra terminal (Bet) domain inhibitor treatment
Genome-wide RNAi Screening Identifies pseudouridine synthase DKC1 promotes CRC proliferation through regulating ribosomal proteins expression
Targeting the EWS/ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy
Spatially Constrained Tandem Bromodomain Inhibition Bolsters Sustained Repression of BRD4 Transcriptional Activity for TNBC Cell Growth
Murine triple negative breast cancer
Combinatorial treatments targeting MAPK and PI3K/mTOR pathways in metastatic melanoma
Transcriptomic analysis of T84 colon carcinoma cell line treated with trametinib, JQ1 or their combination
Transcriptomic analysis of trametinib-resistant HCT116 colorectal carcinoma cells compared to the parental control cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on